Circulating IL-16 correlates with multiple proinflammatory cytokines in rheumatoid arthritis, supporting its role as a mediator promoting inflammation.
Answers are grounded in this paper and cite their sources.
IL-16 associations with RA cytokines support its mediator role; leaves open causal and therapeutic implications.
Sir, Interleukin 16 (IL‐16), also known as lymphocyte chemoattractant factor, is generally considered to play a decisive role in most immune and inflammatory responses. But contradictory reports exist for the importance of IL‐16 in the regulation of rheumatoid synovitis. CD4 and CD8 T‐lymphocytes, monocytes, eosinophils, epithelial cells and fibroblasts found in the rheumatoid arthritis (RA) synovium were found to produce IL‐16. After binding to its receptor molecule, CD4, IL‐16 induces different kinds of intracellular signal transduction and expression of T‐cell surface molecules [1], resulting in the stimulation of CD4+ T‐cells and monocytes, causing them both to migrate into inflamed tissues and stimulating their proliferation. On the other hand, the binding of IL‐16 to CD4 leads to suppression of T‐cell receptor (TCR)/CD3‐mediated activation, resulting in T‐cell anergy, as observed in the mixed lymphocyte reaction [2]. These contradictory functions of IL‐16 are reflected in different reports about the role of IL‐16 in RA. Klimiuk et al. [3] described an anti‐inflammatory activity of synovial tissue‐infiltrating CD8+ T‐cells mediated by the release of IL‐16. In contrast, Franz et al. [4] found elevated IL‐16 levels in the synovial fluid correlating with parameters of inflammation and they demonstrated synovial fibroblasts as a source of IL‐16 using in situ hybridization experiments. The aim of this study was to look for correlations between circulating levels of IL‐16 and known proinflammatory cytokines in RA patients and controls, in order to provide more evidence that IL‐16 acts as a mediator promoting inflammation. Non‐heparinized blood was collected from 48 patients who fulfilled the 1987 revised American College of Rheumatism criteria for RA [5] and 40 healthy controls. Characteristics of these subjects are given in Table 1. Cytokine levels were determined using commercial ELISA systems from Roche Molecular Biochemicals, Mannheim, Germany (IL‐16), R&D Systems, Minneapolis, MN, USA [IL‐1β, tumour necrosis factor α (TNF‐α), IL‐6, the soluble IL‐6 receptor (sIL‐6R) and the soluble TNF receptors 1 and 2 (sTNFR1 and ‐R2)] and Immunotech International, Marseille, France (sIL‐2R). For statistical analysis we used the Mann–Whitney U‐test and the Spearman rank correlation coefficient. In RA, serum IL‐16 and serum TNF‐α, IL‐6, sIL‐2R and sTNFR1 and ‐R2 levels were increased significantly compared with non‐RA controls. In RA patients and controls, there were no significant differences in cytokine levels with respect to age or sex. Moreover, in RA patients, there was a close correlation between serum IL‐16 level and serum levels of IL‐1β, TNF‐α, IL‐6, sIL‐2R and sTNFR1 and ‐R2, but not between IL‐16 and sIL‐6R. In RA patients, disease duration was correlated positively with X‐ray disease status and negatively with erythrocyte sedimentation rate (ESR), but not with any cytokine or cytokine receptor tested in this study. Levels of IL‐16, IL‐6, TNF‐α, sIL‐2R and sTNFR1 and ‐R2 were positively correlated with ESR and C‐reactive protein (Table 1). Results obtained were in agreement with the proinflammatory role of IL‐16 as discussed elsewhere. Enhanced expression of IL‐16‐mRNA and an increased number of CD4+ T‐cells were found recently in acute and chronic skin lesions of patients with atopic dermatitis and in allergen‐induced late‐phase nasal responses [6]. Moreover, Lee et al. [7] found that elevated levels of IL‐16 correlated positively with the systemic lupus erthematosus disease activity index. IL‐16‐mediated T‐cell abnormalities, such as activation and clonal anergy, related to a breakdown of self‐tolerance, have been reported repeatedly for this representative autoimmune disease [8]. IL‐16 serum levels correlate with soluble CD4, which is shed from the the CD4 T‐cell surface by activation [7]. These findings indicate an initial stimulation of CD4+ cells in the presence of increased IL‐16 levels, estimating the proinflammatory effect of IL‐16. Interesting similarities were observed between IL‐16‐ and HIV‐1‐induced activation of CD4+ lymphocytes. IL‐16, which is slightly elevated in HIV‐1 infection, and HIV‐1‐gp120 both bind to the CD4 molecule, resulting in expression of HLA class II molecules, the production of IL‐2 and the induction of T‐cell anergy. In agreement with this, autoimmune‐related phenomena, including arthritis, have been described repeatedly in HIV‐1 infection [9]. There are hints of a proinflammatory action of IL‐16 from the mechanism of its generation. Stimulation of IL‐16‐secreting cells leads to cleavage of the C‐terminal region of a preformed pro‐IL‐16 by caspase‐3, resulting in the release of biologically active IL‐16 [10]. Proteinases of the caspase family, known as IL‐1β‐converting enzymes, also process pro‐IL‐1β into active IL‐1β, although there are no significant sequence similarities between the precursors of these two cytokines [10]. Rheumatoid synovial tissue synthesizes large amounts of IL‐1β, which is known to be a key factor in the destruction of cartilage and bone. The positive correlations that we found between IL‐16 and other mediators that are important in promoting inflammatory responses (TNF‐α, IL‐6 and sIL‐2R) may be an additional argument for the proinflammatory role of IL‐16 in RA. The elevated levels of sTNFR seem to be a compensatory response, as discussed elsewhere. In conclusion, IL‐16 appears to be an interesting cytokine for further research and novel therapeutic approaches in this inflammatory disease. Characterization of RA patient and control group n.d., not detected; n.s.=not significant. *P<0.05; **P<0.01. Characterization of RA patient and control group n.d., not detected; n.s.=not significant. *P<0.05; **P<0.01. Correspondence to: J Kaufmann, Department of Internal Medicine IV, Friedrich‐Schiller‐University of Jena, D‐07740 Jena, Germany.
No takes yet. Share an insight, caveat, or question.
Jörg Kaufmann (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: